Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$2.49 - $20.59 $13,428 - $111,041
5,393 Added 27.76%
24,822 $67,000
Q1 2023

May 12, 2023

BUY
$15.95 - $25.18 $240,860 - $380,243
15,101 Added 348.91%
19,429 $363,000
Q4 2022

Feb 10, 2023

SELL
$13.27 - $17.73 $159,744 - $213,433
-12,038 Reduced 73.55%
4,328 $70,000
Q3 2022

Nov 01, 2022

BUY
$11.4 - $14.6 $186,572 - $238,943
16,366 New
16,366 $212,000
Q2 2021

Aug 11, 2021

SELL
$18.57 - $35.68 $21,429 - $41,174
-1,154 Reduced 21.05%
4,328 $115,000
Q3 2020

Nov 17, 2020

BUY
$40.47 - $45.5 $211,739 - $238,056
5,232 Added 2092.8%
5,482 $225,000
Q3 2020

Nov 13, 2020

SELL
$40.47 - $45.5 $211,739 - $238,056
-5,232 Reduced 95.44%
250 $10,000
Q4 2019

Feb 11, 2020

BUY
$34.58 - $48.06 $189,567 - $263,464
5,482 New
5,482 $235,000
Q3 2019

Oct 25, 2019

SELL
$36.98 - $48.45 $338,662 - $443,705
-9,158 Closed
0 $0
Q2 2019

Jul 31, 2019

SELL
$35.13 - $55.53 $62,426 - $98,676
-1,777 Reduced 16.25%
9,158 $0
Q1 2019

May 08, 2019

BUY
$42.83 - $59.91 $95,982 - $134,258
2,241 Added 25.78%
10,935 $593,000
Q3 2017

Nov 09, 2017

BUY
$33.4 - $53.9 $290,379 - $468,606
8,694
8,694 $463,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $31.9M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Great West Life Assurance CO Portfolio

Follow Great West Life Assurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great West Life Assurance CO , based on Form 13F filings with the SEC.

News

Stay updated on Great West Life Assurance CO with notifications on news.